Drugs / HB002.1M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03387566 | Feb 2018 → Feb 2020 | wet macular degeneration | Huabo Biopharm Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB002.1M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387566 ↗ |
| Modality | Protein / enzyme biologic | “a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1” NCT03387566 ↗ |
| Route | Intravitreal | “via intravitreal (IVT) injection” NCT03387566 ↗ |